Anxiety Medications Explained: An Overview for Non-Medical People

Many people facing anxiety may not realize just how many medication options exist to help manage it. This article aims to give a broad overview for those considering or prescribed anxiety medications, focusing on key classes rather than diving deeply into any one. We'll cover which classes work best for specific anxiety disorders, their general pros and cons, and basic mechanisms of action. Remember, medications can be valuable, but they're most effective as part of a holistic plan that includes psychotherapy, exercise, nutrition, mindfulness, work-life balance, and social support. A meta-analysis showed that combining psychotherapy with antidepressants like SSRIs yields better outcomes for anxiety disorders than medication alone (Bandelow et al., 2015). Relying solely on meds might lead to tolerance over time. Always consult a healthcare provider for a personalized evaluation—this isn't a substitute for professional advice.

Neuregen in Scottsdale, AZ (USA) offers a range of treatment options for Anxiety.

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs, such as fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), fluvoxamine (Luvox), citalopram (Celexa), and escitalopram (Lexapro), are often the first-line treatment for various anxiety disorders, including generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety, and panic disorder, as well as depression. Sertraline has FDA approval for several of these, but others are commonly used off-label, which is legal and ethical with proper discussion. A network meta-analysis confirmed SSRIs like escitalopram are effective and acceptable for GAD (He et al., 2019).

They can start working right away for some, but full benefits often take 3–8 weeks or longer. These are generic, affordable, and have a long track record of safety. Side effects are generally milder than older antidepressants, but some experience sexual issues like reduced libido or orgasm difficulty; in those cases, alternatives like tricyclics or MAOIs might suit better. Discontinuation syndrome (withdrawal) is more likely with short-half-life options like paroxetine, but slow tapering minimizes this for most.

Mechanisms aren't fully proven, but SSRIs boost serotonin levels, enhance glial cell function, and increase brain-derived neurotrophic factor (BDNF), correlating with peak effects around 1–2 months. They're ideal for co-occurring anxiety and depression, though high doses can sometimes worsen anxiety—less so with citalopram or escitalopram. A meta-analysis found SSRIs effective across anxiety disorders, with higher doses linked to greater improvement (Jakubovski et al., 2019). They're not addictive. For OCD, higher doses and longer time may be needed. Paroxetine isn't great for older adults due to weight gain risk and other effects.

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs, including venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine (Pristiq), levomilnacipran (Fetzima), and milnacipran (Savella), are similar to SSRIs and often used interchangeably. Venlafaxine acts like an SSRI at low doses but adds norepinephrine boost at higher ones. Most SSRI comments apply here, but SNRIs also enhance norepinephrine, potentially aiding pain relief—duloxetine has FDA approval for certain pains, and milnacipran for fibromyalgia. A meta-analysis showed SNRIs effective for anxiety disorders, though without the dose-response benefit seen in SSRIs (Jakubovski et al., 2019). They're good for anxiety with pain but share discontinuation risks, especially short-half-life ones.

Benzodiazepines

Benzodiazepines like alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), and diazepam (Valium) act quickly—minutes to hours—for acute anxiety, with cumulative effects over weeks. They're useful for panic or severe episodes but highly addictive and dangerous with alcohol or opioids, potentially fatal. Long-term use may link to dementia; a meta-analysis found benzodiazepine use associated with higher dementia risk in elders (Wu et al., 2023). Another review confirmed cognitive impairments persist post-withdrawal (Liu et al., 2020).

Alprazolam is most addictive due to fast onset/short duration, risking rebound anxiety. Longer-acting ones like diazepam last longer but aren't ideal for elders due to sedation, falls, and confusion. They enhance GABA receptors, acting as muscle relaxants and anti-seizure agents too. Always taper slowly to avoid severe withdrawal, even without addiction—physiological dependence can occur. A meta-analysis showed benzodiazepines superior to antidepressants for somatic anxiety symptoms in GAD (Baldwin et al., 2024).

Buspirone

Buspirone is unique for GAD, with potential synergy for depression. It's non-addictive and safer than benzodiazepines. Effects build over 1–2 months via serotonin, dopamine, norepinephrine, and GABA influences, though some notice quicker benefits. A meta-analysis confirmed buspirone's efficacy for GAD with coexisting depression (Gammans et al., 1992). Another showed cognitive benefits alongside low side effects (Du & Li, 2024).

Beta Blockers

Beta blockers like propranolol (Inderal) are off-label for anxiety, blocking adrenaline effects at beta receptors. They're helpful for performance or social anxiety without addiction or cognitive fog, unlike benzodiazepines. Avoid in low blood pressure, heart failure, bradycardia, or asthma. Early research suggested depression risk, but recent questions this. A systematic review found no benefit over placebo or benzodiazepines for social phobia but limited evidence overall (Steenen et al., 2025). Another supported propranolol for stage fright and PTSD-related anxiety (Szeleszczuk & Frączkowski, 2022).

Other Antidepressants

These sedating options like mirtazapine (Remeron), trazodone (Desyrel), and nefazodone (Serzone) help sleep and anxiety, taken at night. Side effects like hangover may fade. Mechanisms boost serotonin and work at other receptors. Mirtazapine is calming, aids appetite/weight gain (good for loss from anxiety), but not for overweight folks. Trazodone is used low-dose for insomnia/anxiety; nefazodone less due to liver risks. A review noted these as alternatives when SSRIs fail (Garakani et al., 2020).

Tricyclic Antidepressants (TCAs)

Older TCAs like imipramine (Tofranil), amitriptyline (Elavil), and desipramine (Norpramin) increase norepinephrine and serotonin but have more side effects, overdose risks, and cardiac concerns than SSRIs/SNRIs. Not ideal for elders due to sedation, low blood pressure, and confusion. Good for anxiety with pain or GI issues. A meta-analysis showed TCAs effective for depressed inpatients, potentially more than SSRIs (Anderson, 1998).

Monoamine Oxidase Inhibitors (MAOIs)

MAOIs like phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), and selegiline (Emsam) boost norepinephrine, serotonin, and dopamine. They may be more effective than SSRIs/SNRIs/TCAs, but limited head-to-head trials exist. Require tyramine-restricted diet to avoid hypertensive crisis—except low-dose selegiline patch. A meta-analysis found MAOIs effective for social anxiety and panic, though evidence is scarce (Baldwin et al., 2025). Used when others fail.

Bupropion (Wellbutrin or Zyban)

Bupropion affects dopamine and norepinephrine, not serotonin. Avoid in seizures or bulimia; helps quit smoking and may reduce other cravings. Energizing, so can worsen anxiety but calm ADHD/ADD. Not typically for anxiety alone. A meta-analysis showed comparable anxiety relief to SSRIs in depression (Papakostas et al., 2008). Good for depression with ADHD/anxiety.

Cannabidiol (CBD) & Medical Marijuana

CBD and marijuana need more research but are safer than alcohol/benzos for overdose. CBD targets the endocannabinoid system, reducing anxiety, seizures, and GI symptoms; FDA-approved for seizures. THC can help or worsen anxiety/psychosis. Sativas may stimulate, indicas calm—oversimplified. A meta-analysis found CBD substantially reduces anxiety (Yao et al., 2024). Another preclinical review supported efficacy (Blessing et al., 2015). Consider after other treatments fail; check interactions.

S-Adenosyl Methionine (SAMe)

SAMe, natural in the body, aids neurotransmitter synthesis and cell maintenance. Mainly researched for depression, limited for anxiety, but similar effects suggest potential. A systematic review found SAMe effective for CNS health, including mood (Baden et al., 2024).

Antihistamines

Antihistamines like diphenhydramine (Benadryl) and hydroxyzine (Vistaril) block histamine receptors; sedating but low addiction risk. Off-label for anxiety in addiction history; help allergies/itching/sleep. Not for elders long-term. A review noted hydroxyzine as the only FDA-approved antihistamine for anxiety (Garakani et al., 2020). Effective in GAD trials (Llorca et al., 2002).

Antipsychotics

Not FDA-approved for anxiety but used off-label, especially with psychosis or bipolar. Risk tardive dyskinesia, metabolic issues, cardiac effects. Quetiapine often for anxiety/insomnia/PTSD. Good for severe OCD. An umbrella review found limited high-quality evidence beyond quetiapine for GAD (Garakani et al., 2024).

Other (e.g., Psilocybin, MDMA, Ketamine)

Emerging psychedelics show promise for PTSD/anxiety. MDMA-assisted therapy reduces PTSD symptoms; ketamine for depression may help secondary anxiety. Microdosing lacks research. Not widely legal yet. A meta-analysis found psychedelics effective for mental disorders like PTSD (Yao et al., 2024). MDMA trials confirmed benefits (Mitchell et al., 2023).

References

Anderson, I. M. (1998). SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depression and Anxiety, 7(Suppl 1), 11-17. https://doi.org/10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA3>3.0.CO;2-8

Baden, K. E. R., McClain, H., Craig, E., Gibson, N., Draime, J. A., & Chen, A. M. H. (2024). S-Adenosylmethionine (SAMe) for central nervous system health: A systematic review. Nutrients, 16(18), 3148. https://doi.org/10.3390/nu16183148

Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., & Wittchen, H.-U. (2024). Meta-analysis of the comparative efficacy of benzodiazepines and antidepressants for psychic versus somatic symptoms of generalized anxiety disorder. Comprehensive Psychiatry, 130, 152479. https://doi.org/10.1016/j.comppsych.2024.152479

Baldwin, D. S., et al. (2025). Safety and efficacy of monoamine oxidase inhibitors in the treatment of anxiety disorders: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 28(Suppl 1), i267. https://doi.org/10.1093/ijnp/pyad067.376

Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015). Efficacy of treatments for anxiety disorders: A meta-analysis. International Clinical Psychopharmacology, 30(4), 183-192. https://doi.org/10.1097/YIC.0000000000000078

Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1

Du, Y., & Li, Q. (2024). Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis. Heliyon, 10(7), e28918. https://doi.org/10.1016/j.heliyon.2024.e28918

Gammans, R. E., Stringfellow, J. C., Hvizdos, A. J., Seidel, W. F., Cohn, J. B., Wilcox, C. S., ... & Rickels, K. (1992). Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology, 25(4), 193-201. https://doi.org/10.1159/000118837

Garakani, A., Freire, R. C., Buono, F. D., Thom, R. P., Larkin, K., Funaro, M. C., Salehi, M., & Perez-Rodriguez, M. M. (2024). Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatrica Scandinavica, 149(4), 295-312. https://doi.org/10.1111/acps.13669

Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020). Pharmacotherapy of anxiety disorders: Current and emerging treatment options. Frontiers in Psychiatry, 11, 595584. https://doi.org/10.3389/fpsyt.2020.595584

He, S., Wu, S., Wang, C., Jiang, A., Xia, W., Li, X., Gao, M., Al-Hawwas, M., & Kong, X. (2019). Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research, 118, 21-30. https://doi.org/10.1016/j.jpsychires.2019.08.009

Jakubovski, E., Johnson, J. A., Nasri, F., Müller-Vahl, K., & Bloch, M. H. (2019). Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depression and Anxiety, 36(3), 198-212. https://doi.org/10.1002/da.22854

Liu, L., Jia, L., Jian, P., Zhou, Y., Zhou, J., Wu, F., & Tang, Y. (2020). The effects of benzodiazepine use and abuse on cognition in the elders: A systematic review and meta-analysis of comparative studies. Frontiers in Psychiatry, 11, 755. https://doi.org/10.3389/fpsyt.2020.00755

Llorca, P.-M., Spadone, C., Sol, O., Danniau, A., Bougerol, T., Corruble, E., ... & Lépine, J.-P. (2002). Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: A 3-month double-blind study. Journal of Clinical Psychiatry, 63(11), 1020-1027. https://doi.org/10.4088/JCP.v63n1112

Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., ... & Davis, A. K. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(9), 2473-2480. https://doi.org/10.1038/s41591-023-02565-4

Papakostas, G. I., Stahl, S. M., Krishen, A., Seifert, C. A., Tucker, V. L., Goodale, E. P., & Fava, M. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Journal of Psychiatric Research, 42(7), 577-587. https://doi.org/10.1016/j.jpsychires.2007.05.012

Steenen, S. A., van Wijk, A. J., van der Heijden, G. J., van Westrhenen, R., de Lange, J., & de Jongh, A. (2025). Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 368, 90-99. https://doi.org/10.1016/j.jad.2024.09.068

Szeleszczuk, Ł., & Frączkowski, D. (2022). Propranolol versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder. International Journal of Molecular Sciences, 23(17), 10099. https://doi.org/10.3390/ijms231710099

Wu, C.-C., Liao, M.-H., Su, C.-H., Poly, T. N., & Lin, M.-C. (2023). Benzodiazepine use and the risk of dementia in the elderly population: An umbrella review of meta-analyses. Journal of Personalized Medicine, 13(10), 1485. https://doi.org/10.3390/jpm13101485

Yao, Y., Guo, D., Lu, T.-S., Liu, F.-L., Huang, S.-H., Diao, M.-Q., Li, S.-X., Zhang, X.-J., Kosten, T. R., Shi, J., Bao, Y.-P., & Lu, L. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research, 335, 115886. https://doi.org/10.1016/j.psychres.2024.115886

Yao, Y., et al. (2024). Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Research, 339, 116049. https://doi.org/10.1016/j.psychres.2024.116049